PT-141 (Bremelanotide) Side Effects and Potentially Permanent Risks: What Women Need to Know

What Is Bremelanotide and Why Does It Matter for Women

Bremelanotide is the only FDA-approved on-demand pharmacotherapy for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike flibanserin, which is taken daily, bremelanotide is injected subcutaneously approximately 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than eight times per month according to the prescribing label.

The drug works at melanocortin receptors in the central nervous system, specifically MC3R and MC4R, rather than acting peripherally on genital blood flow. That central mechanism is why its side-effect profile looks so different from drugs like sildenafil and also why it carries a distinct set of risks you need to understand before your first dose.

FDA approval of bremelanotide (Vyleesi) for HSDD was based on two phase 3 randomized controlled trials, RECONNECT Study 1 and RECONNECT Study 2, which together enrolled 1,247 premenopausal women with generalized acquired HSDD.

Common Side Effects: What Most Women Experience

The most common adverse events are predictable, dose-related, and generally short-lived. Knowing their timeline helps you plan around them.

Nausea

Nausea is the side effect most likely to make women stop using bremelanotide. In the RECONNECT trials, approximately 40% of women reported nausea, compared with 1% in the placebo group. Severe nausea occurred in about 8% of bremelanotide users. Onset is usually within an hour of injection, peaks around one to two hours, and resolves within 12 hours for most women.

The prescribing information recommends taking 400 mg oral ondansetron 30 minutes before the bremelanotide injection if you are prone to nausea, though this adds its own risk of QTc prolongation, which is worth discussing with your prescriber before combining them.

Flushing

Flushing was reported in about 20% of participants across the RECONNECT trials. It tends to affect the face, neck, and chest, appears within the first hour, and fades within two to four hours.

Injection-Site Reactions

Subcutaneous injection into the abdomen or thigh produces local reactions, including bruising, pain, and erythema, in roughly 13 to 17% of women. Rotating injection sites reduces cumulative skin irritation. No cases of serious injection-site necrosis have been reported in the clinical trial dataset.

Headache

Headache affected approximately 11% of women in phase 3 data, compared with 5% in placebo arms. The headache is generally mild, frontal, and resolves within several hours without treatment.

Blood Pressure Changes: A Transient Risk That Requires Monitoring

Every dose of bremelanotide causes a measurable, transient increase in blood pressure. In the RECONNECT trials, mean systolic blood pressure rose by approximately 6 mmHg and diastolic pressure by approximately 4 mmHg, beginning within one hour of dosing and resolving within 12 hours. Heart rate fell by approximately 5 beats per minute over the same window, a compensatory vagal response.

This pattern is mild for most women. For women with pre-existing hypertension or cardiovascular disease, though, even a transient pressor effect adds risk. The FDA label states that bremelanotide is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.

What This Means at Different Life Stages

Reproductive years (20s to early 40s): Blood pressure is generally well-controlled in this group, and the transient pressor effect is unlikely to be clinically significant in normotensive women.

Perimenopause (typically mid-40s to early 50s): Estrogen withdrawal contributes to rising blood pressure and increased arterial stiffness. A woman entering perimenopause whose blood pressure is newly creeping upward should have her baseline pressure confirmed before starting bremelanotide and should be monitored with home readings in the first month of use.

Because bremelanotide is only approved for premenopausal women, women who are already postmenopausal fall outside the labeled indication. Off-label use in that group carries additional uncertainty and, given higher baseline cardiovascular risk, needs individual clinical judgment.

Hyperpigmentation: The Side Effect That May Not Go Away

This is the side effect that most competitors underreport and that women most need to understand before starting bremelanotide. Bremelanotide activates melanocortin receptors, which are also involved in skin pigmentation. That same mechanism that influences desire in the CNS also stimulates melanocytes in the skin.

In the pooled RECONNECT safety dataset, focal hyperpigmentation was reported in approximately 1% of women receiving bremelanotide versus none in the placebo group. The affected areas in clinical trials were the face, gums, and breasts. Hyperpigmentation developed with repeated dosing over weeks to months rather than after a single injection.

The key clinical concern is reversibility. In the clinical trial data, hyperpigmentation did not fully resolve in all women after stopping the drug. The FDA label states that in patients who developed hyperpigmentation, the condition was not always reversible after discontinuation. Post-market case reports filed with the FDA Adverse Event Reporting System (FAERS) include accounts of women with persistent gingival (gum) pigmentation and facial darkening months after their last dose, though FAERS reports cannot establish causation independently.

Who Faces Higher Hyperpigmentation Risk

Women with Fitzpatrick skin types IV through VI carry higher baseline melanocyte activity and may be more susceptible to drug-induced hyperpigmentation. No dedicated subgroup analyses by Fitzpatrick type were published from the RECONNECT trials, which is a genuine evidence gap you deserve to know about. The trial population was predominantly white, meaning women of color are making a decision about long-term skin risk on evidence that does not fully represent them.

Monitoring Protocol

If you start bremelanotide, photograph your gumline, face, and breast skin before your first dose and after every four to six weeks of use. Any new darkening should prompt a pause in dosing and a conversation with your prescriber. Do not wait for a scheduled appointment if you notice rapid or diffuse change.

Nausea Severity and the Drug Discontinuation Rate

Nausea in the RECONNECT trials was the primary reason women dropped out. Approximately 13% of women who received bremelanotide discontinued due to adverse events, the majority citing nausea and flushing. This 13% discontinuation rate is higher than what you see with flibanserin (approximately 7% in its key trials) and should factor into your shared decision-making.

Pre-treating with ondansetron reduces nausea meaningfully for many women. Eating a light meal (rather than fasting or eating heavily) before dosing also appears to blunt the nausea response, based on prescriber experience, though the trial protocol tested the drug in a fasted state.

Rare but Documented Adverse Events

Focal Nodule at Injection Site

A small number of women develop a persistent subcutaneous nodule at the injection site with repeated use. These have been benign in all reported cases but can be tender for weeks. Rotating to a new site at least two centimeters from the previous site minimizes this risk.

Transient Loss of Color Vision

Melanocortin receptors are expressed in retinal tissue. Animal studies showed transient retinal changes at high doses. In human trials, no clinically significant ophthalmologic adverse events were reported, though this remains an area where post-market surveillance data is still accumulating. Women with pre-existing retinal conditions should discuss this theoretical risk with an ophthalmologist before starting.

Spontaneous Erection in Men (Not Applicable Here, But Worth Noting)

Bremelanotide was originally studied in men under the name PT-141. In those early trials, priapism was observed, which is why the development program shifted focus. This history is sometimes cited to alarm women, but the anatomical relevance does not translate directly to female physiology. Clitoral engorgement has been noted anecdotally in women using bremelanotide, but this was not systematically measured in the RECONNECT trials.

Hypersensitivity Reactions

Anaphylaxis and angioedema have been reported in post-market data. The rate appears very low, but the drug should be administered for the first time in a setting where you can monitor for 30 minutes and where epinephrine is accessible, or at minimum at a time when you are not alone.

Pregnancy, Lactation, and Contraception: Required Reading Before Your First Injection

Bremelanotide is absolutely contraindicated in pregnancy. Animal studies showed fetal loss and developmental effects at doses that produced systemic exposures comparable to human therapeutic doses. There are no adequate and well-controlled studies in pregnant humans, and given the fetal risk signals in animals, none will be conducted.

What you must do before starting:

1. Confirm you are not pregnant before initiating therapy.
2. Use effective contraception throughout treatment. A barrier method alone may be insufficient if you are at any reproductive risk. Combined hormonal contraception or an IUD is more appropriate.
3. Stop bremelanotide at least one menstrual cycle before attempting conception. The drug has a half-life of approximately 2.7 hours, so it clears quickly, but the one-cycle washout is a conservative safety margin.

If you become pregnant while using bremelanotide: Stop immediately and contact your obstetrician. Report the exposure to the pregnancy pharmacovigilance registry at 1-833-284-2906 so that outcomes data can be collected and future women can benefit from the information.

Lactation: It is not known whether bremelanotide or its metabolites transfer into human breast milk. The manufacturer recommends against use during breastfeeding. Because the injection is on-demand rather than daily, one harm-reduction strategy sometimes discussed is a single-dose "pump and dump" protocol, but there is no pharmacokinetic data in lactating women to define a safe discard window. Given the absence of data, avoid use entirely while breastfeeding.

Postpartum women with HSDD: Postpartum HSDD is extremely common, affecting an estimated 15 to 40% of women in the first year after delivery, driven by prolactin elevation, estrogen deficiency, sleep deprivation, and body-image changes. Bremelanotide is not an appropriate solution in this window unless breastfeeding has fully stopped, contraception is confirmed, and a clinician has ruled out other contributing factors like postpartum depression or thyroid dysfunction.

HSDD Across the Life Stages: Who This Drug Is and Is Not Right For

Premenopausal Women (the Approved Population)

The RECONNECT trials enrolled premenopausal women ages 18 and older with acquired, generalized HSDD, meaning the desire problem developed after a period of normal desire and was not situational. If your HSDD is situational (absent only with one partner or in one context), the evidence base for bremelanotide is weaker and relationship-focused or sex therapy approaches have stronger data for your profile.

Women in Perimenopause

Perimenopause brings fluctuating estrogen and progesterone, rising FSH, sleep disruption, and vasomotor symptoms that all independently reduce sexual desire. Bremelanotide acts centrally and does not address the peripheral hormonal contributors. A woman in perimenopause may benefit more from hormone therapy for the underlying hormonal chaos, with bremelanotide as an adjunct if central desire is still blunted after hormones are optimized.

The drug is not approved for perimenopausal women who have crossed into clinical menopause (12 consecutive months of amenorrhea). Off-label use is not supported by controlled trial data.

Women with PCOS

PCOS is associated with elevated androgens, insulin resistance, and a complicated relationship with sexual function. Some women with PCOS report low desire driven by body-image concerns and depression rather than by a primary neurochemical deficit. Bremelanotide has not been studied specifically in women with PCOS. If your HSDD is primarily driven by depression or body-image issues, a serotonergic antidepressant (carefully chosen, since SSRIs worsen desire in some women) or psychological support may be more appropriate first-line options.

Women with Hypertension or Cardiovascular Disease

As noted above, bremelanotide is contraindicated in this group. If you have controlled hypertension on medication, the label does not automatically exclude you, but the decision requires a specific conversation with a clinician who knows your cardiovascular history.

Interactions With Other Drugs Women Commonly Take

Bremelanotide slows gastric emptying. This creates a clinically meaningful interaction with any oral medication that depends on consistent absorption timing, including oral naltrexone (used in the Sinclair Method for alcohol use disorder and sometimes in low-dose naltrexone protocols) and some oral hormonal contraceptives. Take any time-sensitive oral medications at least two hours before your bremelanotide injection.

Indomethacin co-administration in pharmacokinetic studies increased bremelanotide AUC, indicating that NSAIDs may raise drug exposure. Women who routinely use NSAIDs for dysmenorrhea should be aware of this interaction.

The Evidence Gap Women Deserve to Know About

The RECONNECT trials were rigorous for their scope, but they enrolled participants for only 24 weeks. Long-term safety data beyond six months is limited. Hyperpigmentation is the most obvious concern that requires longer follow-up, but we do not yet have data on whether repeated on-demand use over two to five years produces any cumulative CNS, cardiovascular, or skin effects.

Women have historically been underrepresented in cardiovascular and neurological drug trials, and while RECONNECT was conducted exclusively in women, the lack of racial and ethnic diversity and the six-month observation window are real limitations that your prescriber should acknowledge with you.

The FAERS database through 2024 contains several hundred reports for bremelanotide, with nausea, hyperpigmentation, and injection-site reactions dominating. Post-market surveillance is ongoing and the safety picture will sharpen over the next few years.

Practical Checklist Before Your First Dose

Before injecting bremelanotide for the first time, confirm all of the following with your prescriber:

• Pregnancy test is negative and reliable contraception is in place
• Blood pressure is <130/80 mmHg at rest
• No history of cardiovascular disease or stroke
• No current use of indomethacin or naltrexone without prescriber review of the interaction
• Baseline photos of face, gumline, and breast skin are taken and dated
• You know what to do if severe nausea, chest pain, or allergic symptoms develop after dosing
• You understand the drug is to be used no more than once every 24 hours and no more than eight times per month